On July 11, 2017, Rich Pharmaceuticals, Inc. entered into a support and collaboration agreement with Mega Bridge, Inc. (Hypgen), to support Hypgen's development of treatments for Parkinson's Disease. Under the terms of the agreement, the company will provide data, raw materials and advisory support to Hypgen to assist Hypgen with their development of treatments for Parkinson's Disease and the associated regulatory approval process. In exchange, Hypgen will pay the company $100,000 and issue the company 15,000,000 shares of Hypgen common stock.